Comparing WORK Medical Technology Group (NASDAQ:WOK) and ClearPoint Neuro (NASDAQ:CLPT)

WORK Medical Technology Group (NASDAQ:WOK) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations and profitability.

Valuation & Earnings

This table compares WORK Medical Technology Group and ClearPoint Neuro”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WORK Medical Technology Group	$9.81 million	0.00	-$1.07 million	N/A	N/A
ClearPoint Neuro	$36.97 million	9.07	-$25.54 million	($0.91)	-12.29

WORK Medical Technology Group has higher earnings, but lower revenue than ClearPoint Neuro.

Volatility & Risk

WORK Medical Technology Group has a beta of 2.37, indicating that its share price is 137% more volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for WORK Medical Technology Group and ClearPoint Neuro, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WORK Medical Technology Group	1	0	0	0	1.00
ClearPoint Neuro	1	0	2	0	2.33

ClearPoint Neuro has a consensus price target of $14.50, suggesting a potential upside of 29.70%. Given ClearPoint Neuro’s stronger consensus rating and higher probable upside, analysts plainly believe ClearPoint Neuro is more favorable than WORK Medical Technology Group.

Profitability

This table compares WORK Medical Technology Group and ClearPoint Neuro’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
WORK Medical Technology Group	N/A	N/A	N/A
ClearPoint Neuro	-69.08%	-122.17%	-40.69%

Insider and Institutional Ownership

30.1% of ClearPoint Neuro shares are held by institutional investors. 6.9% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

ClearPoint Neuro beats WORK Medical Technology Group on 7 of the 12 factors compared between the two stocks.

About WORK Medical Technology Group

WORK Medical Technology Group Ltd. engages in developing health instruments. It manufactures and sells medical devices, including endotracheal tubes, laryngeal mask airways, heat and moisture exchanging filters, disposable breathing circuits, nebulizer kits, and yankauer suction sets. The company was founded on March 1, 2022 and is headquartered in Hangzhou, China.

About ClearPoint Neuro

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.